Josh Welle

DNP Doctor of Nursing Practice,  CharitĂ© - Universitätsmedizin Berlin 

Location: Africa

Consulting Services

Pharma-CRO-Device Grant Submission

Areas Of Interest

P2X2 Receptor Receptor, Bonzo Heart Associations, American Levels, Certification NASA Corpus Callosum Dysgeneses Development, Psychosexual Healthcare-Associated Pneumonia Russo-Japanese War, 1904-1905 Inhibitors, CGRP-R Mandelonitrile-beta-Gentiobioside Diseases, Endocrine Primary Somatosensory Cortex Systems, Communication Hospital Concept, Cardiovascular Physiological Plasmodium falciparum Merozoite Precursor Surface Coat Protein Ulva Dodecyl Ethyleneglycol Monoether Eukaryotic Initiation Factor 3, Subunit 1 Pyrroles Feeder Layer Cell Non Infective Endocarditis Management Quality Circles Subiculums viruses, Bovine foamy Surgical Stoma Neisseria cinerea Ampicillin Resistance Chloroplast Coupling Factors Evaluation Studies Syndrome, Adie's Lipreading Adhesion, Cell Gingipain Proteases Aortic Valve Stenosis

Professional Narrative

Dr. Josh Welle was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Welle has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Medical Writer, Amgen 1995
Medical Writer, Mayo Clinic 2019

Education

Director Medicine, Yale School of Medicine 2011
Director Medicine, Yale School of Medicine 1993

Referees


Publications

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021 Feb;20(2):101-124. doi: 10.1038/s41573-020-0090-8. Epub 2020 Dec 4. PMID: 33277608; PMCID: PMC7717100.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi: 10.1038/s41578-021-00358-0. Epub 2021 Aug 10. PMID: 34394960; PMCID: PMC8353930.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :